• Ocuphire Announces Six Poster Presentations on Nyxol and APX3330 at the American Academy of Optometry Annual Meeting

    来源: Nasdaq GlobeNewswire / 24 10月 2022 07:56:52   America/Chicago

    FARMINGTON HILLS, Mich., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced acceptance and presentation of six posters featuring Nyxol® and APX3330 at the American Academy of Optometry (AAOPT) 2022 Annual Meeting being held October 26-29, 2022 in San Diego, CA.

    AAOPT 2022: San Diego Convention Center
    Title:Safety and Tolerability of Phentolamine Ophthalmic Solution for Reversal of Mydriasis in Two MIRA Phase 3 Trials 
    Poster #: 260, Exhibit Hall H
    Date/Time:Thursday, October 27, 2022, 4:30 PM – 6:30 PM PT
    Presenter: Justin Schweitzer, OD
      
    Title:Masked Safety of Oral Drug Candidate APX3330 for the Treatment of Diabetic Retinopathy in an Ongoing ZETA-1 Phase 2b Clinical Trial 
    Poster #: 200, Exhibit Hall H
    Date/Time:Thursday, October 27, 2022, 4:30 PM – 6:30 PM PT
    Presenter: Doug Devries, OD
      
    Title:Phentolamine Ophthalmic Solution Rapidly Reverses Pharmacologically Induced Mydriasis in Two Pivotal MIRA Phase 3 Trials
    Poster #: 188, Exhibit Hall H
    Date/Time:Friday, October 28, 2022, 1:00 PM – 3:00 PM PT
    Presenter: Leslie O'Dell, OD
      
    Title:MIRA-4, Clinical Trial Evaluating the Safety and Efficacy of Phentolamine Ophthalmic Solution for Reversal of Pharmacologically Induced Mydriasis in Pediatric Subjects Aged 3-11 Years
    Poster #: 187, Exhibit Hall H
    Date/Time:Friday, October 28, 2022, 1:00 PM – 3:00 PM PT
    Presenter: Shane Foster, OD
      
    Title:Phentolamine Alone and in Combination with Low Dose Pilocarpine Improves Near Vision in Presbyopic Subjects in the VEGA-1 Phase 2 Trial
    Poster #: 186, Exhibit Hall H
    Date/Time:Friday, October 28, 2022, 1:00 PM – 3:00 PM PT
    Presenter: Mitch Ibach, OD
      
    Title:LYNX-1: A Pivotal Phase 3 Randomized Placebo-Controlled Trial of Phentolamine Ophthalmic Solution in Subjects with Dim Light Vision Disturbance 
    Poster #: 185, Exhibit Hall H
    Date/Time:Friday, October 28, 2022, 1:00 PM – 3:00 PM PT
    Presenter: Shane Kannarr, OD

    About Ocuphire Pharma

    Ocuphire is a publicly traded (Nasdaq: OCUP), clinical-stage, ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of refractive and retinal eye disorders. For more information about Ocuphire’s clinical trials, visit https://www.ocuphire.com/clinical-trials.

    Ocuphire Contacts

    Mina Sooch, President & CEO 
    Ocuphire Pharma, Inc. 
    ir@ocuphire.com

    Corey Davis, Ph.D.
    LifeSci Advisors
    cdavis@lifesciadvisors.com

    Bret Shapiro
    Core IR
    brets@coreir.com


    Primary Logo

分享